Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Adds SNPs to Abbott Agreement, Signs LifeSeq Gold Deal with Vertex

Premium

P

ALO ALTO, Calif.--Incyte Pharmaceuticals announced that it has expanded its agreement with Abbott Laboratories to include access to Incyte’s in silico SNP program for an undisclosed amount. The program was developed using a proprietary algorithm to discover common DNA sequence variants by mining Incyte’s LifeSeq Gold database of human genes.

Separately, Vertex Pharmaceuticals announced that it has licensed LifeSeq Gold for use in small molecule drug discovery. The drug company will use the genomic information as part of its chemogenomics discovery effort, which seeks to rapidly and simultaneously design multiple lead classes of drugs directed at protein targets in gene families.

Filed under

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.